Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families

Journal of Lipid Research

Volumn 55, Issue 5, 2014, Pages 939-946

  Kulkarni, Hemant ^a   Meikle, Peter J ^b   Mamtani, Manju ^a   Weir, Jacquelyn M ^b   Almeida, Marcio ^a   Diego, Vincent ^a   Peralta, Juan Manuel ^a   Barlow, Christopher K ^b   Bellis, Claire ^a   Dyer, Thomas D ^a   Almasy, Laura ^a   Mahaney, Michael C ^a   Comuzzie, Anthony G ^a   Göring, Harald H H ^a   Curran, Joanne E ^a   Blangero, John ^a  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Genetics; Insulin resistance; Lipidomics; Lipids; Obesity; Plasma lipidomics; Variance components

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; LIPID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; INSULIN RESISTANCE; LIPIDOMICS; MALE; METABOLIC SYNDROME X; MEXICAN AMERICAN; OBESITY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; BIOLOGY; BLOOD; GENETICS; PEDIGREE; PHENOTYPE; STATISTICS AND NUMERICAL DATA;

ADULT; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MEXICAN AMERICANS; PEDIGREE; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS;

EID: 84899554139     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M044065     Document Type: Article

References (45)

1. Donovan, E. L., S. M. Pettine, M. S. Hickey, K. L. Hamilton, and B. F. Miller. 2013. Lipidomic analysis of human plasma reveals etherlinked lipids that are elevated in morbidly obese humans compared to lean. Diabetol. Metab. Syndr. 5 : 24.
2. Tajima, Y., M. Ishikawa, K. Maekawa, M. Murayama, Y. Senoo, T. Nishimaki-Mogami, H. Nakanishi, K. Ikeda, M. Arita, R. Taguchi, et al. 2013. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis. 12 : 68.
3. Mielke, M. M., and N. J. Haughey. 2012. Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease? Clin. Lipidol. 7 : 525-536.
4. Ishikawa, M., Y. Tajima, M. Murayama, Y. Senoo, K. Maekawa, and Y. Saito. 2013. Plasma and serum from nonfasting men and women differ in their lipidomic profiles. Biol. Pharm. Bull. 36 : 682-685.
5. Laurila, P. P., I. Surakka, A. P. Sarin, L. Yetukuri, T. Hyotylainen, S. Soderlund, J. Naukkarinen, J. Tang, J. Kettunen, D. B. Mirel, et al. 2013. Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arterioscler. Thromb. Vasc. Biol. 33 : 847-857.
6. Rasmiena, A. A., T. W. Ng, and P. J. Meikle. 2013. Metabolomics and ischaemic heart disease. Clin. Sci. (Lond.). 124 : 289-306.
7. Fernando, H., K. K. Bhopale, S. Kondraganti, B. S. Kaphalia, and G. A. Shakeel Ansari. 2011. Lipidomic changes in rat liver after longterm exposure to ethanol. Toxicol. Appl. Pharmacol. 255 : 127-137.
8. Kontush, A., and M. J. Chapman. 2010. Lipidomics as a tool for the study of lipoprotein metabolism. Curr. Atheroscler. Rep. 12 : 194-201.
9. Masoodi, M., and A. Nicolaou. 2006. Lipidomic analysis of twentyseven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20 : 3023-3029.
10. Meikle, P. J., and M. J. Christopher. 2011. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Curr. Opin. Lipidol. 22 : 210-215.
11. Quehenberger, O., A. M. Armando, A. H. Brown, S. B. Milne, D. S. Myers, A. H. Merrill, S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51 : 3299-3305.
12. Chua, E. C., G. Shui, I. T. Lee, P. Lau, L. C. Tan, S. C. Yeo, B. D. Lam, S. Bulchand, S. A. Summers, K. Puvanendran, et al. 2013. Extensive diversity in circadian regulation of plasma lipids and evidence for different circadian metabolic phenotypes in humans. Proc. Natl. Acad. Sci. U. S. A. 110 : 14468-14473.
13. de Mello, V. D., M. Lankinen, U. Schwab, M. Kolehmainen, S. Lehto, T. Seppanen-Laakso, M. Oresic, L. Pulkkinen, M. Uusitupa, and A. T. Erkkila. 2009. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia. 52 : 2612-2615.
14. Graessler, J., D. Schwudke, P. E. Schwarz, R. Herzog, A. Shevchenko, and S. R. Bornstein. 2009. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS ONE. 4 : e6261.
15. Kulkarni, H., P. J. Meikle, M. Mamtani, J. M. Weir, C. K. Barlow, J. B. Jowett, C. Bellis, T. D. Dyer, M. P. Johnson, D. L. Rainwater, et al. 2013. Plasma lipidomic profile signature of hypertension in Mexican American families: specific role of diacylglycerols. Hypertension. 62 : 621-626.
16. Spijkers, L. J., R. F. van den Akker, B. J. Janssen, J. J. Debets, J. G. De Mey, E. S. Stroes, B. J. van den Born, D. S. Wijesinghe, C. E. Chalfant, L. MacAleese, et al. 2011. Hypertension is associated with marked alterations in sphingolipid biology: a potential role for ceramide. PLoS ONE. 6 : e21817.
17. Wopereis, S., M. Radonjic, C. Rubingh, M. Erk, A. Smilde, W. Duyvenvoorde, N. Cnubben, T. Kooistra, B. Ommen, and R. Kleemann. 2012. Identification of prognostic and diagnostic biomarkers of glucose intolerance in ApoE3Leiden mice. Physiol. Genomics. 44 : 293-304.
18. Gross, R. W., and X. Han. 2007. Lipidomics in diabetes and the metabolic syndrome. Methods Enzymol. 433 : 73-90.
19. Puri, R., M. Duong, K. Uno, Y. Kataoka, and S. J. Nicholls. 2012. The emerging role of plasma lipidomics in cardiovascular drug discovery. Expert Opin. Drug Discov. 7 : 63-72.
20. Ollero, M., G. Astarita, I. C. Guerrera, I. Sermet-Gaudelus, S. Trudel, D. Piomelli, and A. Edelman. 2011. Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. J. Lipid Res. 52 : 1011-1022.
21. Wang-Sattler, R., Y. Yu, K. Mittelstrass, E. Lattka, E. Altmaier, C. Gieger, K. H. Ladwig, N. Dahmen, K. M. Weinberger, P. Hao, et al. 2008. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans-first results from the KORA study. PLoS ONE. 3 : e3863.
22. Bergheanu, S. C., T. Reijmers, A. H. Zwinderman, I. Bobeldijk, R. Ramaker, A. H. Liem, J. van der Greef, T. Hankemeier, and J. W. Jukema. 2008. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr. Med. Res. Opin. 24 : 2477-2487.
23. Weir, J. M., G. Wong, C. K. Barlow, M. A. Greeve, A. Kowalczyk, L. Almasy, A. G. Comuzzie, M. C. Mahaney, J. Jowett, J. Shaw, et al. 2013. Plasma lipid profiling in a large population based cohort. J. Lipid Res. 54 : 2898-2908.
24. Uhl, G. R., T. Drgon, C. Johnson, and Q. R. Liu. 2009. Addiction genetics and pleiotropic effects of common haplotypes that make polygenic contributions to vulnerability to substance dependence. J. Neurogenet. 23 : 272-282.
25. Mercado, M. M., J. C. McLenithan, K. D. Silver, and A. R. Shuldiner. 2002. Genetics of insulin resistance. Curr. Diab. Rep. 2 : 83-95.
26. Guillausseau, P. J., D. Tielmans, M. Virally-Monod, and M. Assayag. 1997. Diabetes: from phenotypes to genotypes. Diabetes Metab. 23 (Suppl. 2): 14-21.
27. Mitchell, B. D., L. A. Almasy, D. L. Rainwater, J. L. Schneider, J. Blangero, M. P. Stern, and J. W. MacCluer. 1999. Diabetes and hypertension in Mexican American families: relation to cardiovascular risk. Am. J. Epidemiol. 149 : 1047-1056.
28. Razzouk, L., and P. Muntner. 2009. Ethnic, gender, and age-related differences in patients with the metabolic syndrome. Curr. Hypertens. Rep. 11 : 127-132.
29. MacCluer, J. W., M. P. Stern, L. Almasy, L. A. Atwood, J. Blangero, A. G. Comuzzie, B. Dyke, S. M. Haffner, R. D. Henkel, J. E. Hixson, et al. 1999. Genetics of atherosclerosis risk factors in Mexican Americans. Nutr. Rev. 57 : S59-S65.
30. Voruganti, V. S., J. C. Lopez-Alvarenga, S. D. Nath, D. L. Rainwater, R. Bauer, S. A. Cole, J. W. Maccluer, J. Blangero, and A. G. Comuzzie. 2008. Genetics of variation in HOMA-IR and cardiovascular risk factors in Mexican-Americans. J. Mol. Med. (Berl.). 86 : 303-311.
31. Mamtani, M., P. J. Meikle, H. Kulkarni, J. M. Weir, C. K. Barlow, J. B. Jowett, C. Bellis, T. D. Dyer, L. Almasy, M. C. Mahaney, et al. 2014. Plasma dihydroceramide species associate with waist circumference in Mexican American families. Obesity (Silver Spring). 22 : 950-956.
32. Meikle, P. J., G. Wong, C. K. Barlow, J. M. Weir, M. A. Greeve, G. L. Macintosh, L. Almasy, A. G. Comuzzie, M. C. Mahaney, A. Kowalczyk, et al. 2013. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS ONE. 8 : e74341.
33. Walder, K., D. Segal, J. Jowett, J. Blangero, and G. R. Collier. 2003. Obesity and diabetes gene discovery approaches. Curr. Pharm. Des. 9 : 1357-1372.
34. Bandalos, D. L., and M. R. Boehm-Kaufman. 2009. Four common misconceptions in exploratory factor analysis. In Statistical and Methodological Myths and Urban Legends: Doctrine, Verity and Fable in the Organizational and Social Sciences. E. E. Lance and R. J. Vandenberg, editors. Taylor & Francis, New York. 61-87.
35. Almasy, L., and J. Blangero. 1998. Multipoint quantitative-trait linkage analysis in general pedigrees. Am. J. Hum. Genet. 62 : 1198-1211.
36. Blangero, J., V. P. Diego, T. D. Dyer, M. Almeida, J. Peralta, J. W. Kent, Jr., J. T. Williams, L. Almasy, and H. H. Goring. 2013. A kernel of truth: statistical advances in polygenic variance component models for complex human pedigrees. Adv. Genet. 81 : 1-31.
37. Aguilera, C. M., M. Gil-Campos, R. Canete, and A. Gil. 2008. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin. Sci. (Lond.). 114 : 183-193.
38. Rader, D. J. 2003. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 92 (Suppl. 1): 42-49.
39. Matsuzawa, Y., T. Funahashi, and T. Nakamura. 1999. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann. N. Y. Acad. Sci. 892 : 146-154.
40. Meigs, J. B. 2003. Epidemiology of the insulin resistance syndrome. Curr. Diab. Rep. 3 : 73-79.
41. Zhao, C., J. Mao, J. Ai, M. Shenwu, T. Shi, D. Zhang, X. Wang, Y. Wang, and Y. Deng. 2013. Integrated lipidomics and transcriptomic analysis of peripheral blood reveals significantly enriched pathways in type 2 diabetes mellitus. BMC Med. Genomics. 6 (Suppl. 1): S12.
42. Barber, M. N., S. Risis, C. Yang, P. J. Meikle, M. Staples, M. A. Febbraio, and C. R. Bruce. 2012. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE. 7 : e41456.
43. Kotronen, A., V. R. Velagapudi, L. Yetukuri, J. Westerbacka, R. Bergholm, K. Ekroos, J. Makkonen, M. R. Taskinen, M. Oresic, and H. Yki-Jarvinen. 2009. Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia. 52 : 684-690.
44. Dulloo, A. G., J. Jacquet, G. Solinas, J. P. Montani, and Y. Schutz. 2010. Body composition phenotypes in pathways to obesity and the metabolic syndrome. Int. J. Obes. (Lond.). 34 (Suppl. 2): S4-S17.
45. Yetukuri, L., K. Ekroos, A. Vidal-Puig, and M. Oresic. 2008. Informatics and computational strategies for the study of lipids. Mol. Biosyst. 4 : 121-127.